South America Intravenous Immunoglobulin Market

The intravenous immunoglobulin market in SAM is expected to grow from US$ 783.22 million in 2022 to US$ 1,167.28 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2022 to 2028.

Increasing Geriatric Population

Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the increase in the geriatric population across the region is bolstering the intravenous immunoglobulin market.

Market Overview

The SAM intravenous immunoglobulin market is segmented into Brazil, Argentina, and the Rest of SAM. The region held the smallest portion of the market in the global analysis. The intravenous immunoglobulin market in the region is expected to have growth opportunities during the forecast period. The intravenous immunoglobulin market in the SAM region is expected to grow, owing to increased cases of autoimmune diseases and immunodeficiencies, surge in various research activities, increase in awareness, and rise in healthcare expenditure by the countries of the region. Brazil has made huge strides in the healthcare sector, owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America, and it spent 9.1% of its GDP on healthcare in 2020. The intravenous immunoglobulin market in Brazil is expected to flourish, owing to factors such as surge in vaccination programs and rise in healthcare expenditure by the country.

SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

South America Intravenous Immunoglobulin Strategic Insights

Strategic insights for the South America Intravenous Immunoglobulin provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South America Intravenous Immunoglobulin Report Scope

South America Intravenous Immunoglobulin Regional Insights

The geographic scope of the South America Intravenous Immunoglobulin refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

SAM Intravenous Immunoglobulin Market Segmentation 

The SAM intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

• Based on application, the SAM intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
• Based on distribution channel, the SAM intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
• Based on end user, the SAM intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
• Based on country, the market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022.
• ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.